NVCT Nuvectis Pharma Inc.

FDA Catalyst Company
20.25
+1.25  (+7%)
Previous Close 19
Open 19.9
52 Week Low 3.08
52 Week High 19.97
Market Cap $257,535,329
Shares 12,717,794
Float 6,242,340
Enterprise Value $233,988,416
Volume 15,690
Av. Daily Volume 109,147
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS EST. 1.82
EPS PRIOR. 1.82
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
HC Wainwright & Co. Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 05/10/2022
HC Wainwright & Co. Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 03/02/2022

Latest News

  1. Dose Escalation Portion of NXP800 Phase 1 Study is Ongoing

    NXP800 Unique Discovery and Optimization Program Showcased at the 2022 AACR "New Drugs on the Horizon" Session

    NXP900 Preclinical Potency Against Various Types of Cancer Cells of Squamous Origin Presented at the 2022 AACR Meeting

    Completed Initial Public Offering Raising $16 Million in Gross Proceeds

    FORT LEE, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a biopharmaceutical company focused on the development of precision medicines for serious conditions of unmet medical need in oncology, today reported its financial results for the first quarter of 2022 and provided an update on recent business progress…

    View Full Article
  2. Fort Lee, NJ, April 13, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (NASDAQ:NVCT), ("Nuvectis" or the "Company"), a biopharmaceutical company focused on the development of precision medicines for serious conditions of unmet medical need in oncology, today provided highlights from the poster presentation of NXP900 that took place yesterday at the American Association for Cancer Research ("AACR") Conference in New Orleans.

    "A growing body of scientific evidence provides exciting development opportunities for NXP900" said Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis. "NXP900 is a very potent and selective SRC/YES1 inhibitor with a unique mechanism of action that inhibits both the catalytic and scaffolding functions of the…

    View Full Article
  3. Fort Lee, NJ, April 11, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (NASDAQ:NVCT), ("Nuvectis" or the "Company"), a biopharmaceutical company focused on the development of precision medicines for serious conditions of unmet medical need in oncology, today provided highlights from the oral presentation of NXP800 that took place yesterday at the American Association for Cancer Research ("AACR") Conference in New Orleans.  The presentor, Prof. Paul Workman, is head of the NXP800 program at, and former CEO of, The Institute of Cancer Research, London, UK. 

    "We are very pleased to have been given the opportunity to showcase NXP800 at the New Drugs On The Horizon session of the 2022 Annual AACR Meeting," said Ron Bentsur, Chairman and Chief…

    View Full Article
  4. Completed Initial Public Offering in February 2022, Raising $16.0 million in Gross Proceeds

    Initiated Phase 1a Clinical Trial for NXP800

    Announced Promising Data for NXP900 in Triple Negative Breast Cancer Preclinical Models with an Integrin-Linked Kinase Loss

    Announced Upcoming Oral and Poster Presentations at AACR for NXP800 and NXP900, Respectively

    FORT LEE, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (NASDAQ:NVCT), ("Nuvectis" or the "Company") is a biopharmaceutical company focused on the development of precision medicines for serious conditions of unmet medical need in oncology today reported its financial results for the fiscal year 2021 and provided an update on recent business progress.

    "We founded Nuvectis…

    View Full Article
  5. Fort Lee, NJ, March 10, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT), ("Nuvectis" or the "Company") a biopharmaceutical company focused on the development of precision medicines for serious conditions of unmet medical need in oncology, today announced that an abstract related to NXP800 has been selected for an oral presentation and an abstract related to NXP900 has been selected for a poster presentation at the upcoming 2022 American Association for Cancer Research Meeting (2022 AACR), taking place from April 8th to April 13th in New Orleans. Presentation details are below:

    Oral Presentation

    Title NXP800: A first-in-class orally active, small-molecule HSF1 pathway inhibitor
    Presenter Prof. Paul Workman
    Session
    View Full Article
View All Nuvectis Pharma Inc. News